VRTX · News · 20260809N
Guidance / Outlook
VERTEX PHARMACEUTICALS INC / MA · 2026-08-09 · Importance 66 · Surprise 60 · In source text
Vertex reported strong second-quarter 2026 results, indicating improved quarterly performance. The company upgraded its full-year 2026 revenue guidance, raising its expected revenue outlook. Vertex identified pipeline expansion in pain, kidney, and type 1 diabetes treatments as a longer-term growth and margin-expansion driver.
Key facts
- VERTEX PHARMACEUTICALS INC / MA upgraded its full-year revenue guidance. source
- VERTEX PHARMACEUTICALS INC / MA had a 35.34% one-year total shareholder return. source
- VERTEX PHARMACEUTICALS INC / MA recently announced strong Q2 2026 results. source
- VERTEX PHARMACEUTICALS INC / MA had a 13.99% share price return over 90 days. source
- VERTEX PHARMACEUTICALS INC / MA's earnings are supported by strong cystic fibrosis sales. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | VERTEX PHARMACEUTICALS INC / MA upgraded its full-year revenue guidance. |